相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The future of anti-CD20 monoclonal antibodies: are we making progress?
Waleed Alduaij et al.
BLOOD (2011)
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
Waleed Alduaij et al.
BLOOD (2011)
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
Ekkehard Moessner et al.
BLOOD (2010)
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
Stephen A. Beers et al.
BLOOD (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance
Junji Hiraga et al.
BLOOD (2009)
Mechanisms of killing by anti-CD20 monoclonal antibodies
Martin J. Glennie et al.
MOLECULAR IMMUNOLOGY (2007)
Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis
Holger Schulz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
The shaving reaction: Rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes
PV Beum et al.
JOURNAL OF IMMUNOLOGY (2006)
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
MS Cragg et al.
BLOOD (2003)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
分享论文
